The layoffs first started last month, when Tesla began laying off what was said to be at the time 10 percent of the company’s ...
Swiss drugmaker Sandoz launched its biosimilar Hyrimoz with the same prices as Boehringer and Amgen, whose Amjevita was the first Humira biosimilar to hit the U.S. market, priced at a 5% and 55% ...
Tesla disclosed last month that it expects to book more than $350 million in costs in the second quarter for the mass layoffs ...
The move comes after the Elon Musk-led automaker disbanded its EV charging department following Tesla’s announcement last ...
Amgen today is the biggest biotechnology company in the world, but its plush headquarters, global reach and tens of thousands of employees belie its humble origins. Founded in 1980 as Applied ...
The drug-pricing watchdogs over at the Institute for Clinical and Economic Review tend to be supportive of gene therapy ...
Japanese biotech Ono Pharmaceutical is acquiring Deciphera Pharmaceuticals for $2.4 billion. Bristol Myers Squibb agreed to a ...
April 4 (Reuters) - Boehringer Ingelheim on Thursday said it will lay off some of its salesforce due to poor U.S. sales of its biosimilar version of AbbVie’s blockbuster arthritis treatment Humira.
(Reuters) - Boehringer Ingelheim on Thursday said it will lay off some of its U.S. salesforce due to poor sales there of its biosimilar version of AbbVie’s blockbuster arthritis treatment Humira. The ...